ASX - By Stock
|
SBW |
Re:
Ann: Half Year Results Announcement
|
|
Al.
|
95 |
17K |
3 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
95
|
17K
|
3
|
|
ASX - By Stock
|
SBW |
Re:
Ann: Half Year Results Announcement
|
|
Al.
|
95 |
17K |
3 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
95
|
17K
|
3
|
|
ASX - By Stock
|
SBW |
Re:
Ann: Half Year Results Announcement
|
|
Al.
|
95 |
17K |
3 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
95
|
17K
|
3
|
|
ASX - By Stock
|
GSS |
Re:
Ann: Investor presentation
|
|
Al.
|
59 |
19K |
6 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
59
|
19K
|
6
|
|
ASX - By Stock
|
GSS |
Re:
Ann: Investor presentation
|
|
Al.
|
59 |
19K |
4 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
59
|
19K
|
4
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Investor Presentation
|
|
Al.
|
7 |
2.1K |
4 |
21/08/20 |
21/08/20 |
ASX - By Stock
|
7
|
2.1K
|
4
|
|
ASX - By Stock
|
QOR |
Re:
The birth of a Unicorn perhaps?
|
|
Al.
|
44 |
19K |
4 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
44
|
19K
|
4
|
|
ASX - By Stock
|
GSS |
Re:
Ann: Quarterly report and Appendix 4C
|
|
Al.
|
33 |
10K |
3 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
33
|
10K
|
3
|
|
ASX - By Stock
|
QOR |
Re:
Bright Blue SKY
|
|
Al.
|
59 |
24K |
8 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
59
|
24K
|
8
|
|
ASX - By Stock
|
GSS |
Re:
Ann: Quarterly report and Appendix 4C
|
|
Al.
|
33 |
10K |
15 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
33
|
10K
|
15
|
|
ASX - By Stock
|
GSS |
Re:
Ann: Investor Presentation
|
|
Al.
|
96 |
36K |
0 |
04/06/20 |
04/06/20 |
ASX - By Stock
|
96
|
36K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX signs next-gen anti-cancer platform from Penn & Oxford
|
|
Al.
|
102 |
34K |
13 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
102
|
34K
|
13
|
|
ASX - By Stock
|
TYP |
Re:
Buy Recommendation
|
|
Al.
|
82 |
111K |
2 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
82
|
111K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Presentation
|
|
Al.
|
47 |
17K |
1 |
13/05/20 |
13/05/20 |
ASX - By Stock
|
47
|
17K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS
|
|
Al.
|
188 |
78K |
29 |
06/05/20 |
06/05/20 |
ASX - By Stock
|
188
|
78K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Tracking Valuations
|
|
Al.
|
322 |
171K |
6 |
04/05/20 |
04/05/20 |
ASX - By Stock
|
322
|
171K
|
6
|
|
ASX - By Stock
|
QOR |
Re:
Ann: Family Zone raises $10 million and new Board appointment
|
|
Al.
|
12 |
5.8K |
2 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
12
|
5.8K
|
2
|
|
ASX - By Stock
|
QOR |
Re:
Ann: Family Zone raises $10 million and new Board appointment
|
|
Al.
|
12 |
5.8K |
4 |
29/04/20 |
29/04/20 |
ASX - By Stock
|
12
|
5.8K
|
4
|
|
ASX - By Stock
|
GSS |
Re:
Just When !!
|
|
Al.
|
23 |
8.4K |
3 |
28/04/20 |
28/04/20 |
ASX - By Stock
|
23
|
8.4K
|
3
|
|
ASX - By Stock
|
QOR |
Re:
Ann: Pause in Trading
|
|
Al.
|
10 |
4.1K |
8 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
10
|
4.1K
|
8
|
|
ASX - By Stock
|
QOR |
Re:
Ann: Trading Halt
|
|
Al.
|
2 |
1.5K |
8 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
2
|
1.5K
|
8
|
|
ASX - By Stock
|
GSS |
Re:
Just When !!
|
|
Al.
|
23 |
8.4K |
6 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
23
|
8.4K
|
6
|
|
ASX - By Stock
|
GSS |
Re:
Ann: CE-IVD received for COVID-19 test
|
|
Al.
|
68 |
22K |
1 |
03/04/20 |
03/04/20 |
ASX - By Stock
|
68
|
22K
|
1
|
|
ASX - By Stock
|
GSS |
Re:
Ann: CE-IVD received for COVID-19 test
|
|
Al.
|
68 |
22K |
4 |
03/04/20 |
03/04/20 |
ASX - By Stock
|
68
|
22K
|
4
|
|
ASX - By Stock
|
GSS |
Re:
Ann: CE-IVD received for COVID-19 test
|
|
Al.
|
68 |
22K |
1 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
68
|
22K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
live investor briefing 18th March
|
|
Al.
|
22 |
10K |
5 |
30/03/20 |
30/03/20 |
ASX - By Stock
|
22
|
10K
|
5
|
|
ASX - By Stock
|
MMM |
Re:
Food delivered fresh
|
|
Al.
|
17 |
5.4K |
4 |
21/03/20 |
21/03/20 |
ASX - By Stock
|
17
|
5.4K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
live investor briefing 18th March
|
|
Al.
|
22 |
10K |
0 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
22
|
10K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
live investor briefing 18th March
|
|
Al.
|
22 |
10K |
5 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
22
|
10K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
live investor briefing 18th March
|
|
Al.
|
22 |
10K |
9 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
22
|
10K
|
9
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial
|
|
Al.
|
345 |
953K |
5 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
345
|
953K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial
|
|
Al.
|
345 |
953K |
6 |
02/03/20 |
02/03/20 |
ASX - By Stock
|
345
|
953K
|
6
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial
|
|
Al.
|
345 |
953K |
0 |
02/03/20 |
02/03/20 |
ASX - By Stock
|
345
|
953K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial
|
|
Al.
|
345 |
953K |
5 |
02/03/20 |
02/03/20 |
ASX - By Stock
|
345
|
953K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
PTX - CLinical Trials
|
|
Al.
|
18 |
35K |
8 |
27/02/20 |
27/02/20 |
ASX - By Stock
|
18
|
35K
|
8
|
|
ASX - By Stock
|
VTI |
Re:
Ann: Appendix 4E Full Year Final Results
|
|
Al.
|
3 |
5.6K |
2 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
3
|
5.6K
|
2
|
|
ASX - By Stock
|
VTI |
Re:
Ann: Appendix 4E Full Year Final Results
|
|
Al.
|
3 |
5.6K |
2 |
13/02/20 |
13/02/20 |
ASX - By Stock
|
3
|
5.6K
|
2
|
|
ASX - By Stock
|
HMD |
Re:
Ann: HeraMED appoints US General Manager of Operations
|
|
Al.
|
26 |
14K |
5 |
10/02/20 |
10/02/20 |
ASX - By Stock
|
26
|
14K
|
5
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Appendix 4C - Quarter ended 31 December 2019
|
|
Al.
|
42 |
25K |
0 |
10/02/20 |
10/02/20 |
ASX - By Stock
|
42
|
25K
|
0
|
|
ASX - By Stock
|
PAL |
Re:
Ann: Palla Pharma renegotiates debt facilities on improved terms
|
|
Al.
|
29 |
15K |
1 |
09/02/20 |
09/02/20 |
ASX - By Stock
|
29
|
15K
|
1
|
|
ASX - By Stock
|
PAL |
Re:
Ann: Palla Pharma renegotiates debt facilities on improved terms
|
|
Al.
|
29 |
15K |
0 |
08/02/20 |
08/02/20 |
ASX - By Stock
|
29
|
15K
|
0
|
|
ASX - By Stock
|
PAL |
Re:
Ann: Palla Pharma renegotiates debt facilities on improved terms
|
|
Al.
|
29 |
15K |
0 |
06/02/20 |
06/02/20 |
ASX - By Stock
|
29
|
15K
|
0
|
|
ASX - By Stock
|
PAL |
Re:
Ann: Palla Pharma renegotiates debt facilities on improved terms
|
|
Al.
|
29 |
15K |
0 |
05/02/20 |
05/02/20 |
ASX - By Stock
|
29
|
15K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
PTX200
|
|
Al.
|
9 |
6.6K |
3 |
05/02/20 |
05/02/20 |
ASX - By Stock
|
9
|
6.6K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
PTX200
|
|
Al.
|
9 |
6.6K |
13 |
04/02/20 |
04/02/20 |
ASX - By Stock
|
9
|
6.6K
|
13
|
|
ASX - By Stock
|
HMD |
Re:
Ann: December Quarter Activities Report and Appendix 4C
|
|
Al.
|
12 |
6.8K |
6 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
12
|
6.8K
|
6
|
|
ASX - By Stock
|
PTX |
Re:
Update to PTX-100 and PTX-200 AML
|
|
Al.
|
21 |
13K |
9 |
28/01/20 |
28/01/20 |
ASX - By Stock
|
21
|
13K
|
9
|
|
ASX - By Stock
|
PTX |
Re:
Update to PTX-100 and PTX-200 AML
|
|
Al.
|
21 |
13K |
21 |
28/01/20 |
28/01/20 |
ASX - By Stock
|
21
|
13K
|
21
|
|
ASX - By Stock
|
PTX |
Re:
Update to PTX-100 and PTX-200 AML
|
|
Al.
|
21 |
13K |
6 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
21
|
13K
|
6
|
|
ASX - By Stock
|
PTX |
Re:
Update to PTX-100 and PTX-200 AML
|
|
Al.
|
21 |
13K |
12 |
22/01/20 |
22/01/20 |
ASX - By Stock
|
21
|
13K
|
12
|
|